Ph3 ready hormone therapy company with an injectable, long-acting GnRH antagonist for prostate cancer and benign prostatic hyperplasia. An injectable enables extended drug activity, which is important for indications with active oral antagonists in late-stage development and also approved agent(s). The safety profile looks good with over 415 subjects dosed over 805 times.
22 South Molton Street
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.